Quest Diagnostics Incorporated (NYSE:DGX)
Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.
Quest Diagnostics Incorporated (NYSE:DGX)’s Financial Overview
Quest Diagnostics Incorporated (NYSE) surged 1.14% yesterday to close its trading session at $89.26. The company has 1 year Price Target of $97.65. Quest Diagnostics Incorporated has 52-Week high of $116.49 and 52-Week Low of $78.95. The stock touched its 52-Week High on 116.49 and 52-Week Low on 78.95. The stock traded with the volume of 1.06 Million shares yesterday. The firm shows the market capitalization of $12.23 Billion.
Quest Diagnostics Incorporated (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $1.68/share against the analyst consensus estimate of $1.68/share. The difference between the actual and expected EPS is $0 a share with a surprise factor of 0%.
The firm is trading with SMA20 of 3.06 Percent, SMA50 of 3.95 Percent and SMA200 of -11.14 percent. Quest Diagnostics Incorporated has P/S value of 1.6 while its P/B value stands at 2.28. Similarly, the company has Return on Assets of 8 percent, Return on Equity of 16.8 percent and Return on Investment of 9.3 Percent. The company shows Gross Margin and Operating Margin of 36.9 percent and 15.1 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.5 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 18 analysts offering 12-month price forecasts for Quest Diagnostics Inc have a median target of 97.00, with a high estimate of 117.00 and a low estimate of 72.00. The median estimate represents a +8.67% increase from the last price of 89.26.
Quest Diagnostics Incorporated is expected* to report earnings on 02/14/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 9 analysts’ forecasts, the consensus EPS forecast for the quarter is $1.36. The reported EPS for the same quarter last year was $1.38.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex(r), the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)’s Financial Outlook
The 7 analysts offering 12-month price forecasts for AMAG Pharmaceuticals Inc have a median target of 19.00, with a high estimate of 20.50 and a low estimate of 17.00. The median estimate represents a +19.95% increase from the last price of 15.84.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, AMAG Pharmaceuticals, Inc. has a Consensus Recommendation of 3. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 1.08% and closed its last trading session at $15.84. The company has the market capitalization of $546.35 Million. The stock has 52-week high of $26.1 and 52-Week low of $13.2. The firm touched its 52-Week high on 26.10 and 52-Week low on 12.70. The company has volume of 514717 shares. The company has a total of 34.49 Million shares outstanding.
AMAG Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-1.88/share where the analyst estimated EPS was $-0.79/share. The difference between the actual and Estimated EPS is $-1.09. This shows a surprise factor of -138 percent.
The company has YTD performance of 4.28 percent. Beta for AMAG Pharmaceuticals, Inc. stands at 0.49 while its ATR (average true range) is 0.79. The company has Weekly Volatility of 5.93%% and Monthly Volatility of 4.79%%.
AMAG Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -1.79%, Distance from 50-Day Simple Moving Average of -2.98 percent and Distance from 200-Day Simple Moving Average of -23.29%.
The Company currently has ROA (Return on Assets) of -13.2 percent, Return on Equity (ROE) of -29.5 Percent and Return on Investment (ROI) of -10.3% with Gross margin of 51.6 percent and Operating & Profit margin of -50.9% and -41% respectively.